Shattuck Labs, Inc. (NASDAQ:STTK) makes the list of 12 hot penny stocks to invest in right now, boasting strong performance and growth potential. Analysts are confident in the company’s progress with the SL-325 drug, expecting Phase 1 results in Q2 2026 and emphasizing its clinical potential. Financially, Shattuck Labs remains solid with $86.10 million in cash and investments, positioning the company well for future growth.

In its third-quarter 2025 results, Shattuck Labs reported disciplined execution with R&D expenses at $7.60 million and G&A expenses at $4.10 million. The company reaffirmed progress on the SL-325 trial and is moving towards selecting a bispecific candidate in 2026. With a healthy cash balance, Shattuck Labs is set to advance the drug into Phase 2 trials, despite a net loss of $10.1 million for the quarter.

Shattuck Labs, Inc. (NASDAQ:STTK) is focused on developing innovative therapies for autoimmune and inflammatory diseases, with the SL-325 drug targeting the DR3/TL1A pathway for a complete blockade.

Despite the potential of investing in STTK, some believe that other AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock benefiting from current economic trends, consider exploring other options.

Read more at Yahoo Finance: Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result